ITOS iTeos Therapeutics, Inc. Stock Quote

ITOS [NASD]

Index	-	P/E	-	EPS (ttm)	-1.25	Insider Own	0.71%	Shs Outstand	35.05M	Perf Week	-10.74%
Market Cap	808.54M	Forward P/E	-	EPS next Y	-2.71	Insider Trans	-26.35%	Shs Float	34.80M	Perf Month	-43.67%
Income	-43.40M	PEG	-	EPS next Q	-0.48	Inst Own	77.30%	Short Float	3.79%	Perf Quarter	-38.79%
Sales	-	P/S	-	EPS this Y	-55.40%	Inst Trans	8.13%	Short Ratio	4.40	Perf Half Y	-0.62%
Book/sh	9.22	P/B	2.42	EPS next Y	-19.50%	ROA	-17.50%	Target Price	-	Perf Year	-
Cash/sh	9.27	P/C	2.40	EPS next 5Y	-	ROE	-30.30%	52W Range	17.50 - 47.61	Perf YTD	-34.12%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-53.20%	Beta	-
Dividend %	-	Quick Ratio	22.60	Sales past 5Y	-	Gross Margin	-	52W Low	27.31%	ATR	2.84
Employees	62	Current Ratio	22.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	31.34	Volatility	8.57% 9.56%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	46.60%	Profit Margin	-	Rel Volume	0.58	Prev Close	21.02
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	299.63K	Price	22.28
Recom	1.50	SMA20	-26.31%	SMA50	-37.12%	SMA200	-25.37%	Volume	173,439	Change	5.99%

Oct-08-20

Initiated

Robert W. Baird

Outperform

$45

Aug-18-20

Initiated

Wedbush

Outperform

$45

Aug-18-20

Initiated

SVB Leerink

Outperform

$45

Aug-18-20

Initiated

Piper Sandler

Overweight

$50

Aug-18-20

Initiated

JP Morgan

Overweight

$40

Apr-10-21 08:30AM	iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021 GlobeNewswire
Mar-24-21 04:45PM	iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire -14.49%
Feb-23-21 07:00AM	iTeos to Present at Upcoming Investor Conferences in March GlobeNewswire
Feb-17-21 07:00AM	iTeos to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +7.64%
Jan-25-21 02:13AM	Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions? Simply Wall St.
Jan-05-21 07:00AM	iTeos to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-11-20 02:00PM	Is ITOS A Good Stock To Buy Now? Insider Monkey
Nov-23-20 04:01PM	iTeos to Present at Piper Sandler 32nd Annual Healthcare Conference GlobeNewswire
Nov-12-20 07:01AM	iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
07:00AM	iTeos Appoints Matthew Roden, Ph.D. to Board of Directors GlobeNewswire
Nov-05-20 04:05PM	iTeos to Participate in Upcoming Investor Conferences in November GlobeNewswire
Oct-26-20 08:27AM	We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth Simply Wall St.
Oct-01-20 10:03AM	3 Stocks on J.P. Morgans Radar for Over 60% Upside TipRanks
Sep-08-20 04:05PM	iTeos to Participate in Upcoming Investor Conferences in September GlobeNewswire
Sep-01-20 05:26PM	iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Aug-07-20 08:15PM	Qiagen, Pandion See Activist Actions Barrons.com
Jul-23-20 10:31PM	iTeos Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MPM BioVentures 2014, L.P.	10% Owner	Apr 09	Sale	29.99	119	3,569	3,665,787	Apr 13 04:16 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Apr 09	Sale	29.99	119	3,569	3,665,787	Apr 13 04:15 PM
GADICKE ANSBERT	10% Owner	Apr 09	Sale	29.99	200	5,998	6,004,368	Apr 13 04:15 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Apr 08	Sale	30.52	19,304	589,089	3,655,906	Apr 09 04:09 PM
MPM BioVentures 2014, L.P.	10% Owner	Apr 08	Sale	30.52	19,304	589,089	3,655,906	Apr 09 04:10 PM
GADICKE ANSBERT	10% Owner	Apr 08	Sale	30.52	32,304	985,802	6,004,568	Apr 09 04:47 PM
GADICKE ANSBERT	10% Owner	Apr 07	Sale	32.55	9,678	315,048	6,052,542	Apr 09 04:47 PM
MPM BioVentures 2014, L.P.	10% Owner	Apr 07	Sale	32.55	5,783	188,254	3,700,880	Apr 09 04:10 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Apr 07	Sale	32.55	5,783	188,254	3,700,880	Apr 09 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience